دورية أكاديمية
Internalized FGF-2-Loaded Nanoparticles Increase Nuclear ERK1/2 Content and Result in Lung Cancer Cell Death.
| العنوان: | Internalized FGF-2-Loaded Nanoparticles Increase Nuclear ERK1/2 Content and Result in Lung Cancer Cell Death. |
|---|---|
| المؤلفون: | Miao T; Bioengineering Program, College of Engineering and Mathematical Sciences, Larner College of Medicine, College of Engineering and Mathematical Sciences, University of Vermont, Burlington VT 05405, USA., Little AC; Cellular, Molecular and Biomedical Sciences Graduate Program, University of Vermont, Burlington, Vermont 05405, USA.; Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, VT 05405, USA., Aronshtam A; Department of Medicine, Stem Cell Core, Larner College of Medicine, University of Vermont, Colchester, VT 05446, USA., Marquis T; Department of Medicine, Stem Cell Core, Larner College of Medicine, University of Vermont, Colchester, VT 05446, USA., Fenn SL; Bioengineering Program, College of Engineering and Mathematical Sciences, Larner College of Medicine, College of Engineering and Mathematical Sciences, University of Vermont, Burlington VT 05405, USA., Hristova M; Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, VT 05405, USA., Krementsov DN; Department of Biomedical and Health Sciences, College of Nursing and Health Sciences, University of Vermont, Burlington, Vermont 05405, USA., Vliet AV; Cellular, Molecular and Biomedical Sciences Graduate Program, University of Vermont, Burlington, Vermont 05405, USA.; Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, VT 05405, USA., Spees JL; Cellular, Molecular and Biomedical Sciences Graduate Program, University of Vermont, Burlington, Vermont 05405, USA.; Department of Medicine, Stem Cell Core, Larner College of Medicine, University of Vermont, Colchester, VT 05446, USA., Oldinski RA; Bioengineering Program, College of Engineering and Mathematical Sciences, Larner College of Medicine, College of Engineering and Mathematical Sciences, University of Vermont, Burlington VT 05405, USA.; Department of Mechanical Engineering, College of Engineering and Mathematical Sciences, University of Vermont, Burlington, VT 05405, USA.; Department of Electrical and Biomedical Engineering, College of Engineering and Mathematical Sciences, University of Vermont, Burlington, VT 05405, USA.; Materials Science Program, College of Engineering and Mathematical Sciences, University of Vermont, Burlington, VT 05405, USA. |
| المصدر: | Nanomaterials (Basel, Switzerland) [Nanomaterials (Basel)] 2020 Mar 27; Vol. 10 (4). Date of Electronic Publication: 2020 Mar 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101610216 Publication Model: Electronic Cited Medium: Print ISSN: 2079-4991 (Print) Linking ISSN: 20794991 NLM ISO Abbreviation: Nanomaterials (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, [2011]- |
| مستخلص: | : Innovative cancer treatments, which improve adjuvant therapy and reduce adverse events, are desperately needed. Nanoparticles provide controlled intracellular biomolecule delivery in the absence of activating external cell surface receptors. Prior reports suggest that intracrine signaling, following overexpression of basic fibroblast growth factor (FGF-2) after viral transduction, has a toxic effect on diseased cells. Herein, the research goals were to 1) encapsulate recombinant FGF-2 within stable, alginate-based nanoparticles (ABNs) for non-specific cellular uptake, and 2) determine the effects of ABN-mediated intracellular delivery of FGF-2 on cancer cell proliferation/survival. In culture, human alveolar adenocarcinoma basal epithelial cell line (A549s) and immortalized human bronchial epithelial cell line (HBE1s) internalized ABNs through non-selective endocytosis. Compared to A549s exposed to empty (i.e., blank) ABNs, the intracellular delivery of FGF-2 via ABNs significantly increased the levels of lactate dehydrogenase, indicating that FGF-2-ABN treatment decreased the transformed cell integrity. Noticeably, the nontransformed cells were not significantly affected by FGF-2-loaded ABN treatment. Furthermore, FGF-2-loaded ABNs significantly increased nuclear levels of activated-extracellular signal-regulated kinase ½ (ERK1/2) in A549s but had no significant effect on HBE1 nuclear ERK1/2 expression. Our novel intracellular delivery method of FGF-2 via nanoparticles resulted in increased cancer cell death via increased nuclear ERK1/2 activation. Competing Interests: The authors declare no conflict of interest. |
| References: | Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H1956-65. (PMID: 18775851) Clin Cancer Res. 2015 Jun 15;21(12):2684-94. (PMID: 26078430) Breast Cancer Res Treat. 1999 Jul;56(2):153-67. (PMID: 10573108) Cells. 2019 May 29;8(6):. (PMID: 31146385) J Control Release. 2017 Jun 28;256:170-181. (PMID: 28414151) Oncologist. 2004;9(4):422-41. (PMID: 15266096) Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504. (PMID: 17532091) J Proteomics. 2014 Jan 16;96:82-91. (PMID: 24220302) J Control Release. 2009 May 5;135(3):259-67. (PMID: 19331853) Exp Hematol. 2002 Apr;30(4):297-305. (PMID: 11937263) Biomacromolecules. 2009 Jan 12;10(1):19-24. (PMID: 19072041) J Biol Chem. 2001 Jan 12;276(2):1545-54. (PMID: 11031252) Macromol Biosci. 2011 Jul 7;11(7):882-8. (PMID: 21491603) Methods Enzymol. 2008;438:77-93. (PMID: 18413242) Cell Commun Signal. 2015 Apr 10;13:24. (PMID: 25889964) Histochem Cell Biol. 2012 Jun;137(6):703-18. (PMID: 22527693) Cancer Res. 2009 Nov 15;69(22):8645-51. (PMID: 19903855) Clin Cancer Res. 2012 Apr 1;18(7):1855-62. (PMID: 22388515) J Cereb Blood Flow Metab. 2009 Dec;29(12):1914-23. (PMID: 19654588) Cancer Discov. 2013 Mar;3(3):264-79. (PMID: 23418312) Front Pharmacol. 2012 Jul 17;3:141. (PMID: 22822401) Lung Cancer. 2001 Dec;34 Suppl 2:S165-70. (PMID: 11720760) Biochim Biophys Acta. 1996 Jul 24;1312(3):237-42. (PMID: 8703993) Ann Oncol. 2014 Mar;25(3):552-63. (PMID: 24265351) Sarcoma. 2011;2011:325238. (PMID: 21437219) CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415) CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855) ACS Appl Mater Interfaces. 2016 Jul 20;8(28):17775-17783. (PMID: 27378419) J Control Release. 2003 Jul 31;90(3):261-80. (PMID: 12880694) Growth Factors. 2006 Mar;24(1):21-44. (PMID: 16393692) Biomater Sci. 2015 Jul;3(7):891-3. (PMID: 26221930) Am J Physiol. 1993 May;264(5 Pt 1):C1219-30. (PMID: 7684560) Nat Rev Cancer. 2014 Aug;14(8):535-46. (PMID: 25056707) Prog Polym Sci. 2012 Jan;37(1):106-126. (PMID: 22125349) Mol Biol Cell. 2012 Mar;23(5):864-80. (PMID: 22238363) Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301. (PMID: 7638184) Pharmacol Ther. 2017 Nov;179:171-187. (PMID: 28564583) PLoS One. 2013;8(1):e54391. (PMID: 23349873) Nat Commun. 2016 Jan 20;7:10485. (PMID: 26786866) Biochem J. 2004 Jan 1;377(Pt 1):159-69. (PMID: 14505488) Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15155-60. (PMID: 25288756) Biomaterials. 2012 Apr;33(11):3279-305. (PMID: 22281421) J Cell Physiol. 2007 Mar;210(3):784-97. (PMID: 17117479) FEBS J. 2010 Jan;277(1):2-21. (PMID: 19843174) Bioessays. 2006 May;28(5):504-14. (PMID: 16615083) Mayo Clin Proc. 2008 May;83(5):584-94. (PMID: 18452692) Mol Vis. 2000 Nov 06;6:222-31. (PMID: 11073556) Stem Cell Res Ther. 2017 May 25;8(1):119. (PMID: 28545562) Cell Tissue Res. 2005 Apr;320(1):99-113. (PMID: 15714281) Curr Cancer Drug Targets. 2009 Aug;9(5):639-51. (PMID: 19508171) J Biol Chem. 2003 Jan 3;278(1):479-85. (PMID: 12397076) Acta Biomater. 2015 Oct;26:274-85. (PMID: 26300335) Biochem Soc Trans. 2012 Feb;40(1):224-9. (PMID: 22260695) Exp Cell Res. 2008 Dec 10;314(20):3701-11. (PMID: 18930044) J Cell Physiol. 2007 Dec;213(3):690-8. (PMID: 17503459) J Biol Chem. 2004 Sep 17;279(38):40153-60. (PMID: 15247275) Acta Biomater. 2015 Nov;27:53-65. (PMID: 26340886) Nat Rev Cancer. 2010 Feb;10(2):116-29. (PMID: 20094046) Biomaterials. 1999 Apr;20(8):773-83. (PMID: 10353660) Int J Cancer. 1999 Oct 29;83(3):415-23. (PMID: 10495436) Drug Dev Ind Pharm. 2002 Jul;28(6):621-30. (PMID: 12149954) J Control Release. 2014 Oct 28;192:57-66. (PMID: 24979209) |
| معلومات مُعتمدة: | R01 HL132264 United States HL NHLBI NIH HHS; R01HL085646 United States NH NIH HHS; R01HL085210 United States NH NIH HHS; R01HL132264 United States NH NIH HHS; R01NS073815 United States NH NIH HHS |
| فهرسة مساهمة: | Keywords: ERK1/2; cancer cell death; intracellular FGF-2; lung cancer; nanoparticles |
| تواريخ الأحداث: | Date Created: 20200402 Latest Revision: 20210803 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7221911 |
| DOI: | 10.3390/nano10040612 |
| PMID: | 32230722 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!